UPDATE 1-Sumitomo Dainippon Pharma investing $3 bln in Swiss Roivant in overseas push
* Dainippon to buy 10% stake in Roivant and interests in 5 units * Schizophrenia treatment Latuda to lose US exclusivity in 2023 * Japan pharma firms grapple with declining Dainippon
Read more